Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.38 extracted from

  • Poenitz, V.; Pritchard, D.; Grundt, H.; Nilsen, D.W.
    Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase (2006), J. Thromb. Thrombolysis, 22, 199-203.
    View publication on PubMed
Search for more literature for 3.4.21.38

Application

Application Comment Organism
medicine plasma variations of different types of XIIa following thrombolytic treatment analyzed Homo sapiens

Molecular Weight [Da]

Molecular Weight [Da] Molecular Weight Maximum [Da] Comment Organism
additional information
-
 plasma variations of different forms of XIIa analyzed by ELISA assays Homo sapiens

Organism

Organism UniProt Comment Textmining
Homo sapiens P00748 coagulation factor XII, precursor; patients with acute ST-elevation myocardial infarction (STEMI), treated with thrombolytic therapy
-

Source Tissue

Source Tissue Comment Organism Textmining
blood venous blood samples Homo sapiens
-

Specific Activity [micromol/min/mg]

Specific Activity Minimum [µmol/min/mg] Specific Activity Maximum [µmol/min/mg] Comment Organism
additional information
-
 changes of plasma variations of different types of XIIa in relation to thrombolytic therapy by administration of tenecteplase (TNK-tpa), a thrombolytic with a high fibrin specify, blood samples obtained prior to, within, and four days after administration of thrombolytic therapy, ELISA assays measuring different types of XIIa described Homo sapiens

Substrates and Products (Substrate)

Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
additional information changes of plasma variations of different types of XIIa measured followed by thrombolytic therapy of patients with acute ST-elevation myocardial infarction Homo sapiens ?
-
 ?

Synonyms

Synonyms Comment Organism
coagulation factor XIIa
-
 Homo sapiens